James A. Lebovitz

james-lebovitz

James A. Lebovitz

Partner

Philadelphia | Cira Centre, 2929 Arch Street, Philadelphia, PA, United States of America 19104-2808
+1 215 994 2510 | +1 215 994 2222

New York | Three Bryant Park, 1095 Avenue of the Americas, New York, NY, United States of America 10036-6797
+1 212 698 3891 | +1 212 698 3599


vCard
PDF

James A. Lebovitz is a partner in Dechert's corporate and securities group and a member of the firm's Policy Committee. He represents clients in securities transactions, mergers and acquisitions, strategic alliances and general corporate matters. He has extensive experience advising public and privately-held corporations in the life sciences, healthcare, financial and business services sectors, business development companies (BDCs) and other specialty finance companies, and investment banks in corporate transactions and financings.

Having previously worked in-house as general counsel of a publicly-traded company, Mr. Lebovitz brings a particularly strong commercial perspective when representing clients in transactions. In fact, Chambers USA, a referral guide to leading lawyers in the United States, which consistently recognizes Mr. Lebovitz as a leading lawyer for corporate/M&A and private equity as well as capital markets, described him as a "consummate professional," "collaborative, thoughtful, commercial lawyer" who “is down to earth and stands out as a leader" and “knows just how to get the deal done.” Mr. Lebovitz is also recognized as a leading lawyer for corporate law, securities law, mergers and acquisitions law, leveraged buyouts and private equity law, and biotechnology law in The Best Lawyers in America, is listed as a "Life Sciences Star" in LMG Life Sciences, and was recently named a "Highly regarded" lawyer for M&A in the IFLR1000. In addition, Mr. Lebovitz has also been recognized for his extensive capital markets: debt and equity offerings and mergers and acquisitions experience by The Legal 500 (U.S.), which has praised him for his “unique combination of nuts and bolts wisdom, as well as experienced counsel in complicated matters” and has described him as "exceptional."

Mr. Lebovitz is the chair of Dechert’s firm-wide lawyer hiring committee and previously served as partner responsible for associate development. From 2000 to 2005, he served as chair of the firm’s business and technology practice group.

Mr. Lebovitz joined Dechert in July 1999 as a partner in the Philadelphia office following three years as the general counsel of a national, publicly traded, physician practice management company.

Experience

In the last few years alone, Mr. Lebovitz has advised on a wide range of transactions, including:

  • FS Investment Corporation (NYSE: FSIC) in its merger with Corporate Capital Trust, Inc. (NYSE: CCT), two publicly-listed, business development companies (BDCs) advised by FS/KKR Advisor, to create the second largest publicly-traded BDC by assets under management. 
  • HFF, Inc. (NYSE: HF) in its US$2 billion acquisition in a cash and stock merger with Jones Lang LaSalle (NYSE: JLL).
  • FS Investment Corporation II, FS Investment Corporation III, FS Investment Corporation IV and Corporate Capital Trust II in their merger to create the second largest BDC by assets under management.
  • JetPay Corporation (NASDAQ: JTPY), a leading provider of vertically integrated solutions for businesses including card acceptance, processing, payroll, payroll tax filing, human capital management services, and other financial transactions, in connection with its US$184 million acquisition by NCR Corporation (NYSE: NCR). Previously advised JetPay on several financings and transactions, which were preceded by the representation of Universal Business Payment Solutions Acquisition Corporation, a special purpose acquisition company (SPAC), in its US$72 million initial public offering of common stock, and subsequent acquisition of two operating companies, Jet Pay, a real-time card and ACH processor as well as merchant account provider, and A D Computer, a comprehensive payroll and tax filing service.
  • Bravo Brio Restaurant Group, Inc. (Nasdaq: BBRG), the owner and operator of two Italian restaurant brands (BRAVO! Cucina Italiana and Brio Tuscan Grille), in its US$161 million initial public offering and US$74 million secondary offering, followed by its ultimate US$100 million going-private sale to Spice Private Equity.
  • FS Investments, a leading alternative investment manager, in connection with its partnership with KKR, a leading global investment firm, to create the largest business development company (BDC) platform, with US$18 billion in combined assets under management. 
  • FS Investment Corporation, FS Energy & Power Fund, FS Investment Corporation II, FS Investment Corporation III, and FS Investment Corporation IV, five business development companies, in connection with their continuous offerings of US$2.6 billion, US$1.5 billion, US$2 billion, US$4 billion and US$2.6 billion, respectively, of their common stock.
  • Covance Inc., a leading clinical research organization (CRO) providing drug development services, in its: US$2.2 billion ten-year strategic alliance with Sanofi-Aventis and its related US$25 million acquisition of Sanofi's research and development sites in Porcheville, France and Alnwick in the United Kingdom, US$1.6 billion ten-year strategic alliance with Eli Lilly and Company, and its acquisition of the Gene Expression Laboratory from Merck.
  • Adolor Corporation, a biotechnology company, in its US$415 million sale to Cubist Pharmaceuticals Inc., which included an innovative contingent payment right valued at up to US$225 million. Previously advised Adolor on its initial public offering and subsequent follow-on offerings of common stock as well as M&A transactions and general corporate matters.
  • HFF, Inc., a commercial real estate capital intermediary, in its US$257 million initial public offering of Class A common stock and secondary offerings of common stock.
  • Underwriters, led by JP Morgan and Goldman Sachs, in connection with numerous public offerings of common stock by Amicus Therapeutics, Inc. (NASDAQ: FOLD), a biopharmaceutical company focused on rare genetic diseases.
Education
  • Yale College, B.A., 1979, Editor-in-Chief of the Yale Daily News
  • University of Virginia School of Law, J.D., 1982, Notes Editor of The Virginia Journal of International Law
  • University of Cambridge, LL.M., 1983
Admissions
  • Pennsylvania
  • New York
Memberships
  • Trustee of Choate Rosemary Hall and Vice Chair of the Board
  • Member of the Corporate Council of The Barnes Foundation
  • Former trustee of the Philadelphia Museum of Art, Rhody Squash and The Baldwin School
  • Former president and current member of the Board of Trustees of the Samuel S. Fleisher Art Memorial
Speaking Engagements
  • Permanent and Private Capital in the Time of COVID-19: Where We've Been and Where We're Going — Dechert LLP, Virtual Conference (August 20, 2020)
  • 2017 Permanent Capital Summit — Dechert LLP, New York , NY (March 08, 2017) 
  • Current Trends in Permanent Capital: What Alternative Managers Need to Know Now — Dechert LLP, New York, NY ( January 22, 2015) 
  • Forging a Launch Pad for Emerging Growth IPOs — The Burrill Report Podcast, Philadelphia, PA (April 06, 2012)
  • Investments in Russian Pharma Market — Russian-American Pharmaceutical Conference, Philadelphia, PA (April 27, 2010)